An influx of biosimilars may be coming to the Medicare Part D market in 2023 as multiple manufacturers launch biosimilars of Humira. This white paper explores the dynamics affecting biosimilars in Medicare Part D and key stakeholder considerations under the current and proposed Part D benefit design for 2024.
This report was commissioned by the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center.
Share this page
Biosimilars in Medicare Part D: Pricing dynamics and considerations
What are the dynamics affecting biosimilars in Medicare Part D and what can be in store for 2023?